WholesaleInvestor

04 June 2010

Atlantic Healthcare - Renowned expert Professor Derek Jewell to chair Atlantic Healthcare’s European faculty of leading IBD specialists

Professor Jewell, of Oxford University and John Radcliffe Hospital, Oxford, is one of Europe's leading experts in the treatment of IBD and has been Chairman of the International Organisation for the Study of IBD and is a past-President of the British Society of Gastroenterology.

Part of the remit of Atlantic Healthcare’s European IBD Faculty will be to help the Company to progress alicaforsen, a breakthrough for the treatment of pouchitis and explore its use in the treatment of other IBD conditions.  Alicaforsen is an anti-inflammatory, intercellular adhesion molecule (“ICAM-1”) inhibitor that acts by switching off a key protein that causes inflammation in the gastro-intestinal tract.

Professor Derek Jewell, Chairman of Atlantic’s European IBD Faculty commented:

“Alicaforsen has the potential to become a real breakthrough for the treatment of Inflammatory Bowel Diseases where there still remains a major unmet need. I have patients currently suffering with recurrent pouchitis and for whom existing treatments have failed.  For these patients, there are no approved products and there are few alternatives to major surgery.  I look forward to helping Atlantic Healthcare respond to the needs of these patients through a Named Patient Supply programme and wider international availability following further clinical development.”

Atlantic Healthcare’s first drug – alicaforsen – a breakthrough treatment for Inflammatory Bowel Diseases, is about to go into production ahead of launch.

With a very strong management team of “asset hunters”, a sound strategy for acquisitions and rapid commercialisation, expect further similar exciting products to be acquired which can bring early returns to investors.

For more information

www.atlantichc.com

steve.hobbs@atlantichc.com


To view the Atlantic Healthcare page on WI please CLICK HERE.